Neurocrine Biosciences, Inc.
General ticker "NBIX" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $12.8B (TTM average)
Neurocrine Biosciences, Inc. follows the US Stock Market performance with the rate: 61.0%.
Estimated limits based on current volatility of 1.3%: low 130.96$, high 134.49$
Factors to consider:
- Total employees count: 1800 (+28.6%) as of 2024
- Top business risk factors: Product commercialization failure, Market competition, Reimbursement risks, Intellectual property risks, Customer concentration
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [110.89$, 163.79$]
- 2025-12-31 to 2026-12-31 estimated range: [109.20$, 162.75$]
Financial Metrics affecting the NBIX estimates:
- Negative: with PPE of 41.6 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 24.22 > 18.33
- Negative: negative Industry operating cash flow (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 8.41 > 6.04
- Positive: 0.04 < Operating cash flow per share per price, % of 4.33
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -0.92 <= -0.62
Short-term NBIX quotes
Long-term NBIX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,488.70MM | $1,887.10MM | $2,355.30MM |
| Operating Expenses | $1,239.70MM | $1,636.20MM | $1,784.80MM |
| Operating Income | $249.00MM | $250.90MM | $570.50MM |
| Non-Operating Income | $-35.10MM | $81.20MM | $-84.50MM |
| Interest Expense | $7.10MM | $4.60MM | $126.60MM |
| R&D Expense | $463.80MM | $565.00MM | $731.10MM |
| Income(Loss) | $213.90MM | $332.10MM | $486.00MM |
| Taxes | $59.40MM | $82.40MM | $144.70MM |
| Profit(Loss)* | $154.50MM | $249.70MM | $341.30MM |
| Stockholders Equity | $1,707.80MM | $2,232.00MM | $2,589.70MM |
| Inventory | $35.10MM | $38.30MM | $57.40MM |
| Assets | $2,368.70MM | $3,251.40MM | $3,718.70MM |
| Operating Cash Flow | $339.40MM | $389.90MM | $595.40MM |
| Capital expenditure | $16.50MM | $28.30MM | $38.20MM |
| Investing Cash Flow | $-177.10MM | $-467.10MM | $-126.80MM |
| Financing Cash Flow | $-234.30MM | $65.30MM | $-486.70MM |
| Earnings Per Share** | $1.61 | $2.56 | $3.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.